Group 1 - The core point of the article is the announcement by Kehua Bio (SZ 002022) regarding the resignation of Ms. Luo Fang as the Chief Financial Officer due to retirement, and the appointment of Mr. Zang Xianfeng as the new CFO [1] - The company's revenue composition for the year 2024 is entirely from the biological products sector, accounting for 100.0% [1] - As of the report date, Kehua Bio has a market capitalization of 3.4 billion yuan [1] Group 2 - Related news includes the appointment of Jin Xiangyu as CFO of ST Ningke [2] - Bao Xin Technology's Xu Yexiang has resigned from the positions of director and CFO [2] - Lianjiang Co. has appointed Liu Peiyuan as its CFO [2]

Group 1 - The company Kewah Bio announced the convening of its 10th Board of Directors meeting on July 31, 2025, via telecommunication voting [2] - The meeting reviewed the proposal regarding the appointment of the company's Chief Financial Officer [2] - For the year 2024, the company's revenue composition is entirely from the biopharmaceutical sector, accounting for 100.0% [2]

Group 1 - The core business of Kehua Bio is entirely focused on the biopharmaceutical sector, with a revenue composition of 100% from biological products for the year 2024 [1] Group 2 - On July 31, Kehua Bio announced the resignation of Ms. Luo Fang from the position of Chief Financial Officer due to retirement, along with her other roles in the company's subsidiaries [3] - The company has appointed Mr. Zang Xianfeng as the new Chief Financial Officer, following a nomination by the company's president and approval by the board of directors [3]